Items Tagged ‘MDS’

August 31st, 2016

Revlimid® Reduces Need for Blood Transfusions in Some Myelodysplastic Syndromes

By

The agent Revlimid (lenalidomide) reduces the need for blood transfusions among patients with lower-risk, non-del (5q) myelodysplastic syndromes who are dependent upon red blood cell transfusions, but are not eligible for erythropoiesis-stimulating agents. These results were recently published in the Journal of Clinical Oncology. Myelodysplastic syndromes (MDS) refer to a group of diseases in which […]

View full entry

Tags: clinical trial, General Myelodysplastic Syndrome, lenalidomide, MDS, Myelodysplastic Syndrome, News, RBC, revlimid


December 30th, 2015

Myeloablative Treatment Regimens Superior to Reduced Intensity Treatment for AML and MDS Patients Undergoing Stem Cell Transplant

By

Hematopoietic Stem Cell Transplant (SCT) is a standard and potentially curative treatment for individuals with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Historically only high dose myeloablative treatment regimens were utilized since they were thought necessary to eradicate the malignant cells in the bone marrow. In recent years, SCT physicians have increasingly used reduced […]

View full entry

Tags: Acute Myeloid Leukemia, Allogeneic Stem Cell Transplant, AML, General Myelodysplastic Syndrome, hematopoietic stem cell transplant, Leukemia, MDS, Myelodysplastic Syndrome, News, sct, Stem Cell Transplant


December 14th, 2015

Prospective Study Shows Age Doesn’t Affect Survival Outcomes in Patients with Myelodysplastic Syndrome (MDS) Who Receive a Hematopoietic Cell Transplant (HCT)

By

Results from a prospective study of 1,280 patients with myelodysplastic syndrome (MDS) showed that survival at 100 days and at two years following hematopoietic cell transplant (HCT) for patients aged 65 and older is comparable to patients aged 55 to 64. The study demonstrates that age alone should not be a determinant when considering HCT […]

View full entry

Tags: HCT, hematopoietic cell transplant, MDS, Medicare, Myelodysplastic Syndrome, News, Stem Cell Transplant


August 8th, 2014

Exposure to Some Inflammatory Bowel Disease Drugs May Increase Leukemia Risk

By

Thiopurines are an established treatment for inflammatory bowel disease (IBD) patients.  They are used to reduce inflammation and provide symptom relief.  Thiopurine immunosuppressive drugs have now been reported to increase the risk of acute myelod leukemia and myelodysplastic syndrome, a rare bone marrow disorder, seven-fold among IBD patients. These data were recently reported in a […]

View full entry

Tags: Acute Myeloid Leukemia, AML, cancer prevention, General Myelodysplastic Syndrome, Health and Wellness, Leukemia, MDS, Myelodysplastic Syndrome, News, Screening/Prevention Leukemia, thiopurines